Literature DB >> 28875321

Admission-to-discharge temperature reduction in decompensated heart failure is associated with rehospitalization.

H R Omar1, R Charnigo2, M Guglin3.   

Abstract

INTRODUCTION: Decreasing body temperature on first follow-up visit-relative to discharge-predicts early rehospitalization in heart failure (HF). We studied whether admission-to-discharge temperature reduction was associated with increased HF rehospitalization in the ESCAPE trial.
METHODS: We compared patients with or without ≥1 °C decrease in temperature from admission-to-discharge. The study endpoint was rehospitalization due to HF for up to 6 months after discharge.
RESULTS: Among 354 patients (average age 57 years, 73% men) with recorded admission and discharge temperature, 22 (6.2%) had an admission-to-discharge temperature reduction ≥1 ºC. Patients with admission-to-discharge temperature reduction ≥1 ºC had higher frequency of rehospitalization for HF (68.2% vs. 44.3%, estimated odds ratio [OR] 2.697, 95% confidence interval [CI] 1.072-6.787, P = 0.029) despite a significantly higher admission temperature. On multivariate analysis, admission-to-discharge temperature reduction ≥1 ºC predicted rehospitalization for HF (OR 2.02, 95% CI 1.028-3.966, P = 0.041) after adjustment for age, BMI, baseline Na, creatinine, ejection fraction and discharge NYHA class. A standard logistic model treating temperature change as a continuous variable, and a model using a restricted cubic spline, did not demonstrate a statistically significant relationship between temperature reduction and HF rehospitalization. Subsequently, an altered logistic model was fit expressing the log odds of HF rehospitalization as a piecewise linear function of temperature decrease; this model did demonstrate statistical significance (P = 0.013) with an estimated odds ratio of 1.140 per 0.1 ºC beyond 0.5 ºC.
CONCLUSION: Admission-to-discharge temperature reduction ≥1 ºC is an unfavorable prognostic sign associated with future rehospitalization due to HF.

Entities:  

Keywords:  Heart failure; Hypothermia; Morbidity; Mortality; Rehospitalization

Mesh:

Year:  2017        PMID: 28875321     DOI: 10.1007/s00059-017-4612-z

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  15 in total

1.  Hypothermia is an independent predictor of short and intermediate term mortality in acute systolic heart failure: Insights from the ESCAPE trial.

Authors:  Hesham R Omar; Maya Guglin
Journal:  Int J Cardiol       Date:  2016-06-25       Impact factor: 4.164

2.  Admission body temperature and mortality in elderly patients hospitalized for heart failure.

Authors:  Brahmajee K Nallamothu; Saeed Payvar; Yongfei Wang; Mikhail Kosiborod; Frederick A Masoudi; Edward P Havranek; JoAnne M Foody; S Ward Casscells; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2006-06-20       Impact factor: 24.094

3.  2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

4.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.

Authors:  Cynthia Binanay; Robert M Califf; Vic Hasselblad; Christopher M O'Connor; Monica R Shah; George Sopko; Lynne W Stevenson; Gary S Francis; Carl V Leier; Leslie W Miller
Journal:  JAMA       Date:  2005-10-05       Impact factor: 56.272

5.  Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure.

Authors:  J L Rodríguez-García; A Paule; J Domínguez; J R García-Escribano; M Vázquez
Journal:  Int J Cardiol       Date:  1999-08-31       Impact factor: 4.164

6.  Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.

Authors:  Saeed Payvar; John A Spertus; Alan B Miller; S Ward Casscells; Peter S Pang; Faiez Zannad; Karl Swedberg; Aldo P Maggioni; Kimberly J Reid; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2013-07-15       Impact factor: 15.534

7.  Haemodynamic and neurohumoral effects of cold pressor test in severe heart failure.

Authors:  A Westheim; I Os; E Thaulow; S E Kjeldsen; J Eritsland; I K Eide
Journal:  Clin Physiol       Date:  1992-01

8.  The prognostic importance of different definitions of worsening renal function in congestive heart failure.

Authors:  Stephen S Gottlieb; William Abraham; Javed Butler; Daniel E Forman; Evan Loh; Barry M Massie; Christopher M O'connor; Michael W Rich; Lynne Warner Stevenson; James Young; Harlan M Krumholz
Journal:  J Card Fail       Date:  2002-06       Impact factor: 5.712

9.  Seasonal congestive heart failure mortality and hospitalisation trends, Quebec 1990-1998.

Authors:  D Ehrmann Feldman; R Platt; V Déry; C Kapetanakis; D Lamontagne; A Ducharme; N Giannetti; M Frenette; E J Beck
Journal:  J Epidemiol Community Health       Date:  2004-02       Impact factor: 3.710

10.  Acute hemodynamic improvement by thermal vasodilation in congestive heart failure.

Authors:  C Tei; Y Horikiri; J C Park; J W Jeong; K S Chang; Y Toyama; N Tanaka
Journal:  Circulation       Date:  1995-05-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.